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a  b  s  t  r  a  c  t
Pancreatic  adenocarcinoma  is  one  of  the deadliest  human  solid  tumors  in the  developed
countries  characterized  by high  resistance  toward  chemotherapeutic  treatment.  We  have
previously  shown  that silencing  of the pro-survival  protein  kinase  CK2  by  RNA  interfer-
ence  contributes  to enhance  the  cytotoxicity  of  the  chemotherapeutic  agent  2′,2′-diﬂuoro
2′-deoxycytidine  (gemcitabine).  Initial  experiments  showed  that  pentachlorophenol  (PCP)
inhibits CK2  and  induces  cell  death  in  human  pancreatic  cancer  cell  lines.  We  report  here
evidence that  exposure  of  this  type  of  cells  to PCP  induces  caspase-mediated  apoptosis,
inhibition  of  the  lysosome  cysteine  protease  cathepsin  B  and  mitochondrial  membrane
depolarization.  Beside  cellular  inhibition  of CK2,  the  analysis  of  signaling  pathways  dereg-
ulated  in pancreatic  cancer  cells  revealed  that  PCP  causes  decreased  phosphorylation  levels
of NF-B/p65,  suppresses  its nuclear  translocation  and  leads to activation  of JNK-mediated
stress  response.  Surprisingly,  exposure  to PCP  results  in increased  phosphorylation  levels  of
AKT at the  canonical  S473  and T308  activation  sites  supporting  previous  data  showing  that
AKT phosphorylation  is  not  predictive  of  tumor  cell  response  to  treatment.  Taken  together,
our study  provides  novel  insights  into  the effects  induced  by the  exposure  of  pancreatic  can-
cer cells  to  chlorinated  aromatic  compounds  posing  the  basis  for more  advanced  studies  in
vivo.
© 2014  The  Authors.  Published  by Elsevier  Ireland  Ltd.  This  is  an  open  access  article  under
Y-NC-Nthe CC  B
1. Introduction
Protein kinases play an important role in the resistance
of cancer cells to the cytotoxic effects of chemotherapeu-
tic drugs. Mutations and aberrant activation of this class
of  enzymes is often linked to alteration of intracellular
signal transduction pathways that control cell growth, dif-
ferentiation, survival and motility [for a review see [1]].
∗ Corresponding author at: Department of Biochemistry and Molecular
Biology, University of Southern Denmark, Campusvej 55, 5230 Odense M,
Denmark. Tel.: +45 65502388; fax: +45 65502781.
E-mail address: bag@bmb.sdu.dk (B. Guerra).
http://dx.doi.org/10.1016/j.toxrep.2014.10.027
2214-7500/© 2014 The Authors. Published by Elsevier Ireland Ltd. This is an open ac
licenses/by-nc-nd/3.0/).D  license  (http://creativecommons.org/licenses/by-nc-nd/3.0/).
Consequently, the connection between deregulated pro-
tein  kinases and cancer led to the identiﬁcation of small
molecule compounds able to regulate the activity of this
class  of enzymes. In this respect, previous research focus-
ing  on the selection of compounds with a unique speciﬁcity
toward individual protein kinases has shifted, in recent
years, to the identiﬁcation of drugs with broad speciﬁcity
but high toxicity, thus, representing a therapeutic alterna-
tive  to current treatment regimens.
Protein kinase CK2 is a pleiotropic and constitutively
active serine/threonine kinase composed of two  catalytic
subunits  and/or ′ and two regulatory -subunits. Evi-
dence so far collected, suggests that this enzyme plays a
signiﬁcant role in regulating cell survival and conferring
cess article under the CC BY-NC-ND license (http://creativecommons.org/
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esistance to apoptotic cell death [2–4]. In this respect,
tudies on pancreatic cancer cells, that are notoriously
esistant to chemotherapeutic drugs currently employed
n  the clinics, revealed that down-regulation of CK2 by
NA  interference signiﬁcantly enhances cell death induced
y  gemcitabine treatment [5]. Perhaps, this effect should
ot  come as a surprise since overexpression of CK2 has
een  documented in all cancer types so far investigated
nd associated with the aggressiveness of the tumor [2,6].
igher  than average CK2 activity offers a number of selec-
ive  advantages to the tumors, hence, its inhibition or
own-regulation would consequently weaken this growth
dvantage. In this respect, the identiﬁcation of small
olecule compounds able to inhibit signiﬁcantly the activ-
ty  of CK2 has become an important goal for the successful
reatment of cancer.
Recently,  the screening of small molecule compound
ibraries provided by the National Cancer Institute (NCI)
nder  the Developmental Therapeutics Program (DTP),
as  led to the identiﬁcation of C11 a two-components
i.e. PCP and DMA) cell permeable mixture able to inhibit
ndogenous CK2 and induce signiﬁcant cell death in human
ancreatic cancer cells. We  have closely investigated the
ffects  of C11 and identiﬁed pentachlorophenol (PCP) as its
ctive  component. PCP is a phenol derivative that has been
xtensively used as a wood preservative, insecticide and
ungicide [7,8]. PCP undergoes oxidative dechlorination
o form tetrachlorohydroquinone (TCHQ), a more toxic
etabolite of PCP [9,10]. PCP toxicity seems to be related
ainly to TCHQ-mediated uncoupling of oxidative phos-
horylation and the generation of reactive oxygen species
ROS)  in mitochondria [11,12]. Although it has been shown
o  promote tumor growth [13], studies suggesting that
his  compound and its derivative can induce cell death
re  sparse [14,15]. This work was initiated by our prelim-
nary  observations that PCP induces inhibition of CK2 in
n  ATP-competitive manner. The aim of this study was to
ontribute  to the knowledge of the effects of PCP in human
ancreatic cancer cells and to shed light on the intracellular
ignaling pathways involved in PCP-induced cytotoxicity.
o  the best of our knowledge, this is the ﬁrst contribution
n the characterization of PCP at the molecular level in this
ype  of cells.
.  Materials and methods
.1.  Kinase assays
Protein  kinase activity measurements of recombi-
ant CK2 and CK222 were performed in 40 l of
 reaction mixture containing varying concentrations of
11,  PCP or dimethylallylamine (DMA), as indicated in
he  ﬁgure legends, 25 mM Tris/HCl pH 7.5, 5 mM NaCl
or  CK2 and 150 mM  for CK222, 18.75 mM MgCl2,
.5 mM DTT, 190 M synthetic peptide RRRADDSDDDDD
KinaseDetect, Odense, Denmark), 125 M ATP and 10 Ci
-32P-ATP] (3000 Ci/mmol, Hartmann Analytic, Braun-
chweig, Germany). After incubation at 30 ◦C for 10 min,
he  reactions were stopped on ice and samples were spot-
ed  onto P81 cellulose paper (WhatmanTM, GE Healthcare,
røndby, Denmark). Radioactivity incorporated into therts 1 (2014) 1162–1174 1163
substrate  target was  determined by scintillation counting
in  a 1450 MicroBeta2 Plate counter (PerkinElmer, Waltham,
MA,  USA).
2.2.  Cell culture and treatments
The  pancreatic ductal adenocarcinoma cell lines Panc-1
and  MIA  PaCa-2 (ATCC, Rockville, MD,  USA) were cultured
according to the manufacturer’s guidelines and maintained
at  37 ◦C in a humidiﬁed atmosphere supplemented with 5%
CO2. Cells were treated with C11 (NCI, Bethesda, MD,  USA),
pentachlorophenol (PCP, AccuStandard, New Haven, CT,
USA),  dimethylallylamine (DMA, Chemical point, Deisen-
hofen,  Germany) and TNF (R&D Systems, Abingdon,
United Kingdom) as indicated in the ﬁgure legends. DMSO
(Sigma–Aldrich, Schnelldorf, Germany) was used in all con-
trol  experiments at a ﬁnal concentration not exceeding 0.2%
(v/v).  Cell viability was determined by the WST-1 assay
(Roche, Mannheim, Germany) in a 96-well plate. 24 h after
seeding,  cells were treated with various concentrations of
C11,  PCP and DMA, respectively, for 48 h. WST-1 reagent
was  added to the cells according to the manufacturer’s
instructions and cell viability was  determined 2 h later in a
VersaMax  ELISA microplate reader (Molecular Devices, CA,
USA).
2.3.  Flow cytometry
Cell  death was  determined by propidium iodide
staining as previously described [5,16]. In order to
detect the mitochondrial membrane potential, cells were
incubated with 5 g/ml JC-1 (5,5′,6,6′-tetrachloro-1,1′,3,3′-
tetraethylbenzimidazolylcarbocyanine iodide, Invitrogen,
Carlsbad, CA, USA) for 15 min  at 37 ◦C. Cells were harvested
by  trypsinization, washed in PBS and re-suspended in 1 ml
PBS  prior to analysis by ﬂow cytometry. For each mea-
surement, 10,000 cells were analyzed on a FACSCaliburTM
ﬂow cytometer (Becton and Dickinson, San Jose, CA, USA).
Acquired data were processed by Cell QuestTM Pro software
(Becton and Dickinson).
2.4.  Isolation of a CD24+ stem-cell-like subpopulation of
Panc-1
Isolation of CD24+ cells was performed employing
the CD24 Microbead Kit human (Miltenyi Biotec, Lund,
Sweden) according to the manufacturer’s instructions.
Brieﬂy, treated cells were harvested by incubation with
2  mM EDTA in PBS for 10 min  at 37 ◦C. Cells were labeled
with biotinylated anti-CD24 antibodies and subsequently
incubated with anti-biotin-conjugated microbeads. Com-
plexes  were retained in a magnetic-activated Cell Sorting
(MACS) column. CD24+-cells were eluted after removal of
the  column from the magnetic ﬁeld and re-seeded prior to
treatment.  In order to verify enrichment of stem-cell-like
Panc-1, cells were stained with antibodies directed against
two  surface markers of stem cells, i.e. FITC-conjugated anti-
CD24  antibody and APC-conjugated anti-CD44 antibody,
respectively, both at 1:30 dilution for 30 min  at 4 ◦C (Mil-
tenyi  Biotec) prior to FACS analysis.
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2.5. Isolation of mitochondria
Cells  were harvested by trypsinization and washed
with ice-cold PBS. Mitochondria were isolated by using
the  Mitochondria Isolation Kit–human (Miltenyi Biotec)
according to the manufacturer’s instructions. Brieﬂy, cell
lysates  were incubated with anti-TOM22 (Translocase of
outer  membrane 22 kDa subunit homolog)-microbeads.
Labeled mitochondria were loaded on a MACS column and
subsequently eluted after removal of the column from the
magnetic  ﬁeld.
2.6.  Immunoﬂuorescence staining
For immunoﬂuorescence analysis, cells were grown on
cover  slides and treated as indicated in the ﬁgure leg-
ends. For detection of NF-B/p65, cells were ﬁxed and
permeabilized as previously described [17,18]. Cells were
incubated with rabbit monoclonal anti-NF-B/p65 (Cell
Signaling Technology, Danvers, MA,  USA) overnight at 4 ◦C.
Incubation  with the primary antibody was followed by
labeling  with biotinylated swine anti-rabbit immunoglob-
ulins for 1 h at room temperature and FITC-conjugated
streptavidin (all from Dako, Glostrup, Denmark) for 30 min
at  room temperature. Cells were counterstained with Dapi
(4′6-diamidino-2-phenylindole, Sigma–Aldrich) for 5 min
at  room temperature.
For  the analysis of the mitochondrial membrane poten-
tial,  cells were incubated with JC-1 as described above,
washed twice with growth medium and immediately ana-
lyzed  under a ﬂuorescence microscope.
Cells were analyzed on a Leica DMRBE microscope
equipped with a DFC 420C camera and Leica Applica-
tion Suite V 3.3.0 software (Leica Microsystems, Wetzlar,
Germany) at 400× magniﬁcation.
2.7.  Preparation of whole cell extracts, Western blot
analysis and antibodies
Whole  cell lysates and immunoblotting were as pre-
viously described [16]. The following antibodies were
employed: mouse monoclonal anti-ATP5B, rabbit mono-
clonal  anti-JNK, mouse monoclonal anti-Cdc37, rabbit
polyclonal anti-p38MAPK (all from Santa Cruz Biotechnol-
ogy, Santa Cruz, CA, USA); mouse monoclonal anti-caspase
8,  mouse monoclonal anti-caspase 9, mouse monoclonal
anti-phospho-p38MAPK (T180/Y182), mouse monoclonal
anti-phospho-AKT (S473), rabbit polyclonal anti-phospho-
AKT (T308), mouse monoclonal anti-cytochrome c, rabbit
polyclonal anti-p44/42 MAPK (ERK1/2), rabbit polyclonal
anti-phospho-GSK3 (S9), rabbit monoclonal anti-caspase
3,  rabbit monoclonal anti-phospho-p44/42 MAPK (ERK1/2,
[T202/Y204]), rabbit monoclonal anti-NF-B/p65, rabbit
monoclonal anti-phospho-NF-B/p65  [(S536), all from
Cell  Signaling Technology]; mouse monoclonal anti-
GSK3, anti-PARP and anti-AKT1 (BD Biosciences, CA,
USA);  mouse monoclonal anti--actin (Sigma–Aldrich);
mouse monoclonal anti-CK2/′ (1AD9) and mouse mono-
clonal anti-CK2 (6D5) (both from KinaseDetect); rabbit
polyclonal anti-phospho-JNK [(T183/Y185), Invitrogen,
Carlsbad, CA, USA]. Rabbit polyclonal anti-phospho-Cdc37rts 1 (2014) 1162–1174
(S13) was  kindly provided by Dr. Miyata, Kyoto Uni-
versity, Japan. Secondary antibodies goat-anti-rabbit and
goat-anti-mouse, coupled to alkaline phosphatase, were
purchased from Jackson ImmunoResearch, Newmarket,
United Kingdom. Protein–antibody complexes were visu-
alized  by a chemiluminescent detection system using
CDP-Star (Applied Biosystems, Foster City, CA, USA) sub-
strate  according to the manufacturer’s instructions.
2.8. Cathepsin B activity assay
The measurement of cathepsin B activity was  carried
out with the cathepsin B activity ﬂuorometric assay kit
(BioVision, San Francisco, CA, USA). In brief, cells were col-
lected  by scraping, washed with cold PBS and lysed with
lysis  buffer. 100 g whole cell lysate was  employed for
the  determination of enzyme activity in the presence of
amino-4-triﬂuoromethylcoumarin (AFC) conjugated to the
cathepsin  B sequence target Ac-RR (Ac-RR-AFC, 200 M
ﬁnal  concentration in the assay). Fluorescence emission
was  measured with a ﬂuorometer (SPEX Fluorolog F2C, NJ,
USA)  employing a 400 nm excitation ﬁlter and a 505 nm
emission ﬁlter. Acquired data were processed by DataMax
software (Jobin YvonTM, NJ, USA).
2.9. Statistical analysis
All  experiments were carried out at least three times
and with triple measurements, if not otherwise stated.
Standard deviation values (S.D.) are indicated in the dia-
grams  as error bars. Statistical signiﬁcance of results was
calculated with the Student’s t-test (two-tailed, same vari-
ance).  Statistical signiﬁcance is indicated in the ﬁgure
legends by P values calculated between two sets of data.
3.  Results
3.1. PCP is a newly identiﬁed ATP-competitive inhibitor
of  CK2
A  preliminary chemoluminescence-based screening of a
small  molecule compound library in search of novel protein
kinase  CK2 inhibitors, led to the identiﬁcation of C11, a mix-
ture  of two  individual compounds; i.e. pentachlorophenol
(PCP) and 2-methyl-n-(2-methyl-2-propenyl)-2-propen-
1-amine (dimethylallylamine, DMA) in a 1:1 molar ratio.
C11,  PCP and DMA  (Fig. 1a) were initially assayed for their
ability  to inhibit the kinase activity of CK2. As shown in
Fig.  1b and summarized in Table 1, C11 inhibited both
the  CK2 subunit (IC50 4.96 M)  and CK2 holoenzyme
(IC50 4.64 M)  in the low micromolar range. In the case
of PCP, the IC50 was  3.73 M and 1.99 M for CK2 and
CK2 holoenzyme, respectively. DMA  did not exert any
inhibitory effect on both enzymes indicating that PCP is
the  active component in the C11 mixture. Further, a kinetic
analysis was  performed with two  different PCP concen-
trations (i.e. 1 M and 10 M,  respectively) in order to
address the mechanism by which CK2 is inhibited by
the  aforementioned compounds. As shown in Fig. 1c and
Table  1, Km values increased concomitantly to increas-
ing concentrations of PCP, moreover, the double reciprocal
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Fig. 1. PCP is the active component of C11 exerting ATP site-directed inhibition of CK2. (a) Chemical structures of PCP and DMA  present in C11 in a 1:1 molar
ratio.  (b) The IC50 values for the CK2 subunit and the CK2 holoenzyme were determined by a dose-response curve for each individual compound/mixture,
respectively. Inhibition is expressed in percentage relative to the activity of the enzyme measured in the absence of compound/mixture (i.e. control
experiment).  Results are mean values ± standard deviation (S.D.) from assays run in triplicates. *p < 0.005, **p < 0.001 denote statistical signiﬁcant differences
for  measurements performed with C11 and PCP with respect to control values. (c) Kinetic analysis of enzyme inhibition by PCP. Upper bar-graphs refer
to  Michaelis–Menten kinetics while lower bar-graphs to Lineweaver–Burk plots. Enzyme activity was  determined at various ATP concentrations in the
absence  or presence of two ﬁxed concentrations of PCP, i.e. 1 M and 10 M,  respectively. Results are mean values ± S.D. from experiments run in triplicates.
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Table 1
Determination of IC50 (M),  Vmax and Km values for the inhibition of CK2 and CK222 by C11, PCP and DMA, respectively. Data show Vmax and Km
values ± S.D. of non-linear (i.e. Michaelis–Menten) regression of the obtained values calculated by GraphPad Prism. The results shown represent means of
at  least three independent experiments performed in triplicates.
IC50 C11 (M) ± S.D. IC50 PCP (M) ± S.D. IC50 DMA  (M)
CK2 4.96 ± 0.32 3.73 ± 0.09 –
CK222 4.64 ± 0.39 1.99 ± 0.13 –
PCP  (M) CK2 CK222
Vmax (U/ng)a ± S.D. Km (M)a ± S.D. Vmax (U/ng)a ± S.D. Km (M)a ± S.D.
0 6.7 ± 0.02 47.9 ± 0.73 5.7 ± 0.07 18.7 ± 1.9
1  6.4 ± 0.07 54.0 ± 1.18 6.1 ± 0.17 48.4 ± 3.29
± 4.75 10  6.9 ± 0.14 352.2 
1 U = pmol/min.
a Non-linear regression (Michaelis–Menten) values.
plots indicated that the inhibition is consistent with an
ATP-competitive binding of the enzyme.
3.2. PCP reduces metabolic activity and induces cell
death in human pancreatic cancer cells
We performed a WST-1 viability assay with two human
pancreatic cancer cell lines, i.e. Panc-1 and MIA  PaCa-2, for
studying  the effects of treatment with C11 and its indi-
vidual components. As shown in Fig. 2a, incubation of
cells  with increasing concentrations of C11 or PCP for 48 h
resulted  in progressive cytotoxicity in both cell lines. Sim-
ilar  effects, albeit less pronounced, were obtained when
PCP  and DMA where combined in a 1:1 ratio. Incubation of
cells  with DMA  alone did not result in reduced metabolic
activity indicating that PCP is the component within C11
responsible for the reduced metabolic activity of the
cells.
A  subpopulation of cells within the Panc-1 cell line
exhibits features of cancer stem cells (CSCs) such as exten-
sive  self-renewal, proliferation, tumorigenesis and high
chemoresistance [19,20]. Thus, we asked the question
whether PCP induced cytotoxic effects also in this fraction
of  cells by performing a WST-1 assay. Panc-1 cells were
enriched in CSCs expressing the cell surface markers CD44
and  CD24. The percentage of CD44+/CD24+ cells was  deter-
mined by ﬂow cytometry showing an increase from 4.35%
to  23.33% (Fig. 2b). Panc-1 cells as well as a population of
depleted  and enriched CSCs were left untreated or exposed
to  C11 and PCP, respectively, for 48 h. Data reported in
Fig.  2c show that PCP is toxic to all cell populations in a
dose  dependent manner and independently of the stem-
like  properties of the cells. Next, ﬂow cytometry analysis
was  performed to measure the percentage of cells in sub-
G1  indicative of cell death, in response to C11 and PCP
treatment, respectively, (Fig. 3a). Cells were left untreated
or  incubated with 100 M C11, PCP and DMA  for the indi-
cated  times, respectively. In Panc-1 cells, 72 h incubation
with C11 and PCP resulted in 23% and 29% of hypodiploid
cells (fraction of cells in sub-G1), respectively. In the case
of  MIA  PaCa-2 cells, the percentage varied from 16% (C11
treatment) to 25% (PCP treatment). Control cells or cells
incubated with DMA for 72 h showed similar amounts of
cells  in sub-G1 that was equal to or below 10%.5.0 ± 0.14 384.3 ± 26.55
3.3. The mechanism of cell death involves the extrinsic
and intrinsic pathways of caspase activation and
inhibition of cathepsin B activity
In order to gain insight into the type of cell death
induced by PCP, we  investigated cleavage of PARP as a mea-
sure  of early-stage apoptosis and the cleavage of the major
members of the extrinsic and intrinsic pathways of caspase
activation. Panc-1 and MIA  PaCa-2 cells were incubated
with C11 and PCP at 100 M concentration for 48 h, respec-
tively. As shown in Fig. 3b, cell death activation appears to
occur  through the extrinsic caspase pathways as Western
blot  analysis revealed cleavage of caspase-8, -3 and PARP
as  compared to untreated cells. In the case of caspase-9,
we  observed a decreased intensity of full-length caspase-9
band  in MIA  PaCa-2 cells treated with PCP with respect to
control  cells indicating activation of the intrinsic apoptotic
pathway. However, in the case of Panc-1 cells, there was
no  signiﬁcant difference in the caspase-9 band intensity
between control and PCP-treated cells suggesting activa-
tion  of the sole extrinsic apoptotic pathway.
Cathepsins are a family of lysosomal proteases stored
in  lysosomes as inactive precursors known for their abil-
ity  to initiate apoptotic cell death independent of caspases
[21,22]. However, of the cysteine proteases, cathepsin
B has been often implicated in the invasive and malig-
nant progression of several types of tumors including
pancreas, making this enzyme a relevant marker to can-
cer  [23–25]. Hence, we  addressed the question whether
cathepsin B is involved in the cell death mechanisms of
pancreatic cancer cells. As shown in Fig. 4, cells were
incubated with 100 M C11 and 100 M PCP for 48 h,
respectively. The activity of cathepsin B from whole cell
extracts was  measured by a ﬂuorescence-based assay. The
assay  revealed a decrease of more than 50% in enzyme
activity in both cell types suggesting that PCP-mediated
inhibition of cathepsin B activity contributes to induce cell
death  in the investigated cell lines. Treatment of cells with
150  M temozolomide (TMZ) served as a positive con-
trol  indicating activation of cathepsin B. A negative control
experiment was  performed in parallel in the presence of CB
inhibitor.
Next,  cells were analyzed for the release of cytochrome
c from isolated mitochondria. As shown in Fig. 5a, detec-
tion  of cytochrome c content in MIA  PaCa-2 cells revealed
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Fig. 2. Cytotoxic effects of PCP on human pancreatic cancer cells. (a) Panc-1 and MIA  Paca-2 cells were incubated with increasing concentrations of C11,
PCP,  DMA for 48 h, respectively. PCP+DMA refers to the two individual compounds added to the cells in a 1:1 molar ratio. Cells incubated with solvent
DMSO  (0 M) were used as a control. Cell viability was  determined by the WST-1 assay as described in Section 2. Viability was  determined as a difference
in  absorbance measured at 450 nm and 690 nm (reference) wavelengths, respectively. Values were expressed in percentage relative to control assay. (b)
Flow  cytometry analysis of CD44 and CD24 expression in Panc-1 cells after enrichment. Two phenotypic subpopulations were collected. CD24-depleted
cells  and CD24-enriched cells. Percentage refers to the amount of CD44+/CD24+ cells in whole CD44+-cell population. (c) CD24-depleted and CD24-enriched
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cell  populations were treated with C11 or PCP for 48 h. Cytotoxicity was
nrichment  procedure. Experiments were repeated three times obtainin
ight  replicates) are shown.
hat treatment with C11 and PCP leads to a decreased
rotein band signal with respect to control experiment,
uggesting release of cytochrome c into the cytosol and,
ence,  caspase-mediated activation of apoptotic cell death.
00  M PCP was the most effective concentration. How-
ver, a clear decrease of cytochrome c content was  not
bserved in Panc-1 cells as compared to control experiment
epresented by cells incubated with DMSO.
A hallmark of apoptosis is the loss of mitochon-
rial membrane potential [m, [26,27]]. The release
f  cytochrome c from the mitochondrial intermembrane
pace into the cytosol has been shown to occur prior
he loss of m, locating cytochrome c release as an
pstream event. However, some studies indicated that
elease  of cytochrome c results from the opening of
he  mitochondrial permeability transition pore suggest-
ng  that loss of m is an earlier event in the activation
f death pathways. Therefore, we analyzed the mito-
hondrial m using the lipophilic cationic dye JC-1, ained as described above. Control refers to the cell population before the
r results. Data from a representative experiment (mean values ± S.D. of
sensitive  marker for mitochondria potential that emits
green ﬂuorescence when present at low concentration (i.e.
monomeric form) and orange ﬂuorescence when it accu-
mulates in the mitochondria as aggregates. As shown in
Fig.  5b, incubation of cells with 100 M C11 or 100 M
PCP  for 24 h led to a signiﬁcant loss of orange ﬂuores-
cence emission with respect to control experiments in both
cell  lines indicating severe loss of m. Quantiﬁcation of
orange  ﬂuorescence emission by ﬂow cytometry conﬁrmed
results obtained by ﬂuorescence microscopy (Fig. 5c).
Taken  together, these data indicate that activation of cell
death  by PCP treatment results in mitochondrial depolar-
ization in both cell lines while release of cytochrome c
occurs  solely in MIA  PaCa-2 cells but not in Panc-1 cells.
This  suggests that the type of caspase-dependent activation
of  cell death following PCP treatment is cell type-speciﬁc
and that mitochondrial depolarization and cytochrome c
release  are two events that occur independently from each
other.
1168 S. Schaefer et al. / Toxicology Reports 1 (2014) 1162–1174
Fig. 3. Cell incubation with PCP induces apoptotic cell death in human pancreatic cancer cells. (a) Cells were incubated with DMSO or exposed to 100 M
C11,  PCP and DMA, respectively, for variable incubation times. Cell cycle analysis was performed by ﬂow cytometry. The distribution of cells in the various
phases  of the cell cycle is expressed in percentage. Cell death is indicated by the percentage of cells in the sub-G1 phase. (b) Western blot analysis of markers
for  apoptotic cell death from cells treated with 100 M C11 and PCP, respectively, for 48 h. Control experiments are represented by the analysis of whole
lysates  from cells treated with DMSO. -actin detection was  performed for verifying equal loading. Experiments shown here, were performed three times
obtaining  similar results.
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Fig. 4. Cathepsin B activity in whole cell lysates after treatment of cells with C11 and PCP reveals decreased enzyme activity. Cells were treated with
DMSO  (control experiment), C11 or PCP as indicated in the ﬁgure for 48 h. A positive control experiment was carried out by incubating cells with 150 M
temozolomide  (TMZ) for 48 h. A negative control experiment was performed by adding 2 l CB inhibitor to whole cell lysate (Cathepsin B assay kit, BioVision)
for  2 h. The released ﬂuorochrome AFC is expressed as percentage of ﬂuorescence emitted/sample relative to release of reaction product in DMSO-treated
cells.  *p < 0.005 indicates values with statistically signiﬁcant difference with respect to numbers obtained from DMSO-treated cells. Experiments were
performed  two times with four replicates each.
Fig. 5. Cytochrome c release following C11 or PCP treatment is cell type speciﬁc. (a) The content of isolated mitochondria from cells treated as indicated
in  the ﬁgure for 48 h was  analyzed by Western blot using an antibody directed against cytochrome c. The detection of ATP synthase subunit  (ATP5B)
was  carried out as a control for equal loading. (b) Mitochondrial membrane potential was analyzed by cell staining with JC-1 reagent after the indicated
treatments  for 48 h. JC-1 monomeric form and aggregates in the mitochondria were detected using a BP 525/20; 635/40 ﬁlter allowing the simultaneous
detection  of green and red ﬂuorescence emission. Cell images were taken at 400× magniﬁcation. (c) Quantiﬁcation of the red ﬂuorescence emission was
carried  out by ﬂow cytometry and expressed in percentage relative to DMSO-treated cells. Results are presented as the average of three independent
experiments. *p < 0.005 denotes statistical signiﬁcant difference for measurements performed with cells treated with PCP with respect to control values.
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3.4. PCP-mediated inhibition of CK2 is accompanied by
activation of AKT1 and suppression of NFB/p65 signaling
pathway
Multiple lines of evidence have linked the PI3K/AKT,
mitogen-activated protein kinases family (MAPK) and
NFB  signaling pathways to chemoresistance of pancre-
atic cancer cell lines [28–33]. Given the importance of CK2
in  the regulation of AKT, MAPKs and NFB [5,34–37], we
examined the effects of PCP on the phosphorylation levels
of  the major components of the aforementioned pathways.
Treatment of cells with C11 and PCP, respectively, led to the
inhibition  of endogenous CK2 as shown by the decreased
phosphorylation of the chaperone protein Cdc37 (Fig. 6a),
a  known CK2 substrate target [38], conﬁrming the postu-
lated  inhibition of endogenous CK2 by PCP. The analysis
by  Western blot of major components of the PI3K/AKT
signaling pathway revealed enhanced phosphorylation of
both  canonical regulatory AKT sites, i.e. T308 and S473, and
the  downstream protein target, i.e. GSK3, as also indicated
by  the densitometric analysis of protein band signal inten-
sity,  suggesting that PCP activates rather than suppresses
the PI3K/AKT signaling pathway (Fig. 6b). Analysis of the
MAPK  signaling pathway, revealed enhanced phosphory-
lation of the stress-activated Jun amino-terminal kinase
(JNK)  in both cell lines (Fig. 6c). Finally, treatment of
cells  with C11 and PCP, respectively, resulted in decreased
phosphorylation of NFB/p65 at the activating S536 and
a  concomitant reduction in total NFB/p65 levels in MIA
PaCa-2  cells (Fig. 6d) suggestsuggesting down-regulation
of the NFB-mediated signaling pathway. It has been
shown that the pro-inﬂammatory cytokine tumor necro-
sis  factor- (TNF) induces rapid phosphorylation of IB
and  its ubiquitin-induced degradation. This event is nec-
essary  for NFB/p65 to be released from the complex with
IB  and for its relocation to the nucleus where it exerts
transactivation functions by binding co-activator proteins
[reviewed in [39]]. As incubation with PCP resulted in
decreased phosphorylation of IKK-mediated phosphory-
lation of NFB/p65 at the activating S536, we addressed the
question  whether PCP affected the TNF-mediated translo-
cation  of NFB/p65 into the nucleus. As shown in Fig. 7,
treatment of both cell lines with TNF led to the accumula-
tion of NFB/p65 in the nucleus with respect to DMSO- and
PCP-treated cells, respectively, where NFB/p65 appeared
to  localize in the cytoplasm. However, incubation of cells
with  PCP suppressed TNF-induced migration of NFB/p65
into  the nucleus as indicated by the persistent signal in the
cytoplasm.
4.  Discussion
The study presented here, indicates that PCP is the active
component of C11 exerting cytotoxic effects in human pan-
creatic  cancer cell lines. Our previous studies showed that
simultaneous silencing of the CK2 catalytic subunits by
RNA  interference enhances the sensitivity of these cell lines
toward  chemotherapeutic agents currently used in the clin-
ics  for the cure of advanced pancreatic cancer [[5], for a
review  see [40]]. We  show here that PCP inhibits recom-
binant human CK2 in an ATP-competitive manner as wellrts 1 (2014) 1162–1174
as  the endogenously expressed enzyme as revealed by
the  decreased phosphorylation of the molecular chaper-
one  Cdc37 at S13, a known cellular substrate target of CK2
[Fig.  6 [38]]. Evidence indicates that CK2 supports survival
and  confers resistance to chemotherapeutic treatment
of cancer cells [reviewed in [2,6]]. Hence, PCP-mediated
induction of cell death in human pancreatic cancer cells
reported here, may  be due, at least partially, to the inhi-
bition of endogenous CK2. However, as protein kinase CK2
expression levels have been shown to be elevated in cancer
and  highly proliferating cells, we cannot exclude that other
types  of cancer cells would respond to PCP treatment in a
similar  fashion. The poor prognosis of pancreatic cancer is
in  part attributed to the presence of a subgroup of cancer
stem  cells which account for tumor recurrence due to their
self-renewal, metastatic potential and resistance to cyto-
toxic  drug treatment [19,20]. Interestingly, we show here
that  incubation of a sub-population of Panc-1 cells enriched
in  cancer stem cells with PCP induces a level of cytotoxicity
comparable to the one observed in the cancer stem cells-
depleted population suggesting that PCP treatment lowers
the  intrinsic resistance of cancer stem cells to cell death
induction (Fig. 2).
In  the present study, we  show that PCP induces apop-
totic cell death as demonstrated by cleavage of PARP and
activation of caspase-3 (Fig. 3), both considered a hallmark
of  apoptosis [41,42]. Interestingly, the type of death sig-
nal  generated in the two  cell lines seems to differ and
be  cell type-dependent. In this respect, we show that PCP
treatment of MIA  PaCa-2 cells leads to activation of both
the  extrinsic and intrinsic caspase-mediated apoptotic
pathways as indicated by the cleavage of caspase-8 and
caspase-9, respectively, and the dose-dependent decreased
level  of cytochrome c in the mitochondria (Fig. 5). In the
case  of Panc-1 cells, induction of cell death is mediated
solely by the death receptor-mediated caspase pathway as
indicated  by the cleavage of caspase-8 and lack of signiﬁ-
cant  decrease in the levels of mitochondrial cytochrome c
as  compared to control cells.
Loss of mitochondrial membrane potential is believed
to occur during activation of death pathways and accom-
panied by cytochrome c release. As shown in Fig. 5, both
cell  lines lose their membrane potential during C11 or PCP-
induced  apoptosis as indicated by the remarkable decrease
in  the JC-1 red ﬂuorescence signal. Surprisingly, it appeared
that  decreased m did not correlate with cytochrome c
release  in Panc-1 cells suggesting that these two events
occur independently from each other. In support of these
data,  Johnson et al. [43] proposed that the mitochondria
contribute to the activation of death pathways at various
levels and that release of cytochrome c and mitochon-
dria depolarization are separate and independent events
depending on where the contribution of the mitochondria
in the death pathway resides.
The  analysis of intracellular signaling pathways that
have been shown to be de-regulated in pancreatic cancer
supporting growth and conferring chemoresistance, sug-
gest  that the cytotoxic properties of PCP are not solely
conﬁned to the inhibition of CK2 but also to alteration
of other intracellular signaling molecules. In this respect,
phosphorylation of JNK was  found up-regulated. JNK is part
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Fig. 6. Analysis of cell signaling pathways de-regulated in human pancreatic cancer cells. (a–d) Whole lysate from cells treated as indicated in the ﬁgure for
48  h were analyzed by Western blot employing antibodies directed against the indicated proteins or their phosphorylated form, belonging to the PI3K/AKT,
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rAPK  and NFB signal transduction pathways, respectively. Analysis of t
K2,  and expression levels of the CK2 subunits is also shown. In all expe
lots  refer to quantitation of band signal intensity with ImageJ software. f a family of protein kinases activated in response to a wide
ange  of cellular stresses [44]. Hence, increased phosphor-
lation observed following C11 or PCP treatment might
epresent a stress response accompanying activation of theession and phosphorylation status of Cdc37, an endogenous substrate of
, -actin was detected as control for equal loading. Numbers below the
ents were performed at least three times obtaining similar results.apoptotic  cell death signaling as previously postulated [45].
Unexpectedly, the anti-proliferative response of PCP cor-
related  with increased phosphorylation of AKT S473 and
T308  and a mild effect on AKT protein expression levels
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Fig. 7. Cell incubation with PCP inﬂuences negatively the TNF-induced NFB/p65 translocation into the nucleus. Cells were left untreated or incubated
NF in t
Negativ
tion: 40with  100 M PCP for 48 h. Where indicated, cells were added 20 ng/ml T
immunoﬂuorescence analysis. Nuclei were visualized by DAPI staining. 
secondary  antibody and FITC-conjugated streptavidin. Original magniﬁca
in Mia  PaCa-2 cells (Fig. 6b). At a ﬁrst glance these results
may  appear contradictory as the PI3K/AKT signaling path-
way  has been linked to cell growth and survival and, thus,
one  would expect that this signaling cascade would remain
unaltered or be suppressed during induction of cell death.
However, recent data suggested that cellular outcome
in tumor cell treatment cannot be predicted by changes
in  the phosphorylation status of AKT as induction of its
phosphorylation in the presence of the broad anti-tumor
agent everolimus (RAD0019) has been shown to occur as
a  results of mTORC1 (rapamycin-sensitive kinase complex
containing raptor) inhibition in a rictor-dependent man-
ner  [46]. Further supporting this, a negative feedback loop
has  been described, where mTOR/S6K1 activation results
in  PI3K signaling inhibition by suppressing the insulin
receptor-dependent cascade [47–49]. Hence, it remains to
be  determined whether the anti-proliferative response in
cells  incubated with PCP is accompanied by mTORC1 inhi-
bition  and whether suppression of AKT phosphorylation at
S473  can be induced by rictor down-regulation.he last 15 min  of incubation time. After ﬁxation, cells were subjected to
e control (NC) refers to cells immunostained with only the biotinylated
0×. At least 50 cells were analyzed per treatment condition.
The NFB signaling pathway is implicated in the
regulation of numerous cellular functions including inﬂam-
mation,  proliferation, stress-response and programmed
cell death control. Moreover, its de-regulation has been
linked to chemoresistance of pancreatic cancer cells.
We  have examined the effect of PCP on the acti-
vation of NFB/p65. Our data demonstrate that PCP
leads to decreased phosphorylation of NFkB/p65 at
S536  and reduction of its protein expression levels in
MIA  PaCa-2 cells. NFB/p65 phosphorylation at S536
results in nuclear localization and stimulation of NFB
transactivation functions. We  show here, that the TNF-
mediated stimulation of NFB/p65 is suppressed in the
presence of PCP providing mechanistic evidence that
the  anti-proliferative and pro-apoptotic effects of PCP
are  associated with inhibition of the NFB signaling
pathway.
Apart from the carcinogenic properties of PCP reported
in  previous work, this study shows that PCP exerts
toxic effects in human pancreatic cancer cells involving
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. Conclusion
Data reported here, are consistent with the involve-
ent of three major pro-survival signaling cascades, i.e. the
I3K/AKT/mTOR, MAPK and NF-B pathways but also with
he  inhibition of a nodal pro-survival kinase, i.e. protein
inase CK2. These data aim to provide initial insight into
he  anti-proliferative effects of PCP in pancreatic cancer
ells  and form the basis for more advanced studies on the
echanism of action of chlorinated aromatic compounds
n  vivo.
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